All providers, regardless of where they work have a role in the shift to value-based care, but independent physicians need to have a voice in the transition, said Sibel Blau, MD, medical oncologist at Northwest Medical Specialties, PLLC.
All providers, regardless of where they work have a role in the shift to value-based care, but independent physicians need to have a voice in the transition, said Sibel Blau, MD, medical oncologist at Northwest Medical Specialties, PLLC.
Transcript
What role can independent physicians play in the transition to value-based care?
I think we all have challenges, whether we work in academic centers, or hospitals, or independent practices. I really believe though, as a private practice doctor, we have a chance to change the healthcare system. I think we can make a dent and start from there and grow this idea of going from fee-for-service to a value base.
I think independent physicians need to have a voice and pursue what is felt to be impossible. I think when we get together we know, we saw, what we can create together. We did little projects, we had fun doing it, we showed improvements in healthcare. Now we can grow and do it more globally and by bringing more practices together. I think that we will have a chance to do this without focusing on making millions of millions of dollars or flipping the organization into selling to something to make money.
The purpose is truly providing value-based care in our health system and helping the cost of this country’s huge expenditure in healthcare issues. And then providing the best care to our patients. I think we are able to do that, and I really believe we can get there.
BCI Shows Promise of Personalized Endocrine Therapy in Breast Cancer
January 15th 2025The Breast Cancer Index (BCI) may help identify patients with low-risk breast cancer who could potentially benefit from reduced endocrine therapy, leading to improved quality of life and potentially lower health care costs.
Read More
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen